5-Isopropyl-1-naphthol | 61982-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-Isopropyl-1-naphthol
• 英文别名: 5-(Propan-2-yl)naphthalen-1-ol；5-propan-2-ylnaphthalen-1-ol
• CAS: 61982-96-5
• 化学式: C₁₃H₁₄O
• 分子量: 186.254
• InChiKey: OXVNCTNCWYEWMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-Isopropyl-1-naphthol 生成 5-Propan-2-ylnaphthalene-1,4-dione
  参考文献：
  名称：

  ISHII H.; HANAOKA T.; ASAKA T.; HARADA Y.; IKEDA N., TETRAHEDRON, 1976, NO 32, 2693-2698

  摘要：

  DOI：
• 作为产物：
  描述：

  5-Isopropyl-1-methoxy-naphthalin 、 三溴化硼 以88%的产率得到
  参考文献：
  名称：

  ISHII HISASHI; HANAOKA TADASHI; IKEDA NISABURO, YAKUGAKU DZASSI, YAKUGAKU ZASSNI U. PHARM. SOS. JAR., 1976, 96, NO 10, 11+

  摘要：

  DOI：

文献信息

• Oxidation with Fremy's salt—VIII
  作者：H. Ishii、T. Hanaoka、T. Asaka、Y. Harada、N. Ikeda

  DOI：10.1016/0040-4020(76)80108-1

  日期：1976.1

  It has been shown by a series of experiments on 5-alkyl, 5-halo-, and other 5-substituted 1-naphthol derivatives that the product ratio of the ortho- and para-naphthoquinones formed on oxidation with Fremy's salt is controlled by the bulkiness of the C5-substituent.

  在5-烷基，5-卤代和其他5-取代的1-萘酚衍生物上进行的一系列实验表明，用Fremy's盐氧化形成的邻萘和对萘萘醌的产物比率受C 5-取代基的体积大。
• TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20140128388A1

  公开（公告）日：2014-05-08

  Drug candidates for inhibition of HIV-1 replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-1 viral replication in vitro.

  针对HIV-1复制的药物候选物可以针对Src家族激酶（SFK），例如与病毒的Nef蛋白相互作用的Hck。通过对Nef:SFK复合物中SFK的激酶活性进行测定，鉴定了具有这种抑制活性的化合物。使用激酶测定鉴定的抑制剂的例子包括各种2,3-二氨基喹啉和呋喃[2,3-d]嘧啶。发明的抑制剂被发现可以在体外阻止HIV-1病毒复制。
• Antitumor Agents. 272. Structure−Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues
  作者：Yizhou Dong、Qian Shi、Huei-Chen Pai、Chieh-Yu Peng、Shiow-Lin Pan、Che-Ming Teng、Kyoko Nakagawa-Goto、Donglei Yu、Yi-Nan Liu、Pei-Chi Wu、Kenneth F. Bastow、Susan L. Morris-Natschke、Arnold Brossi、Jing-Yu Lang、Jennifer L. Hsu、Mien-Chie Hung、Eva Y.-H. P. Lee、Kuo-Hsiung Lee

  DOI：10.1021/jm1000858

  日期：2010.3.11

  Neo-tanshinlactone (1) and its previously reported analogues, such as 2, are potent and selective in vitro antibreast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps, with a better overall yield. Structure-activity relationships studies on these compounds revealed some key molecular determinants for this family of antibreast agents. Several derivatives (19-21 and 24) exerted potent and selective antibreast cancer activity with IC50 values of 0.3, 0.2, 0.1, and 0.1 mu g/mL, respectively, against the ZR-75-1 cell lines. Compound 24 was 2- to 3-fold more potent than I against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-BR-3/MCF-7 selectivity. In addition, analogue 2 showed potent activity against it ZR-75-1 xenograft model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines. Further development of lead compounds 19-21 and 24 as clinical trial candidates is warranted.
• US8541415B2
  申请人：——

  公开号：US8541415B2

  公开（公告）日：2013-09-24
• ISHII HISASHI; HANAOKA TADASHI; IKEDA NISABURO, YAKUGAKU DZASSI, YAKUGAKU ZASSNI U. PHARM. SOS. JAR., 1976, 96, NO 10, 11+
  作者：ISHII HISASHI、 HANAOKA TADASHI、 IKEDA NISABURO

  DOI：——

  日期：——